{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:05:31Z","timestamp":1790193931049,"version":"4.1.0"},"reference-count":87,"publisher":"European Respiratory Society (ERS)","issue":"162","license":[{"start":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T00:00:00Z","timestamp":1634688000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir Rev"],"accepted":{"date-parts":[[2021,3,2]]},"published-print":{"date-parts":[[2021,12,31]]},"abstract":"<jats:p>Thymic tumours are rare thoracic malignancies, that may be aggressive and difficult to treat. The pillars of the management include pathological review, consideration of differential diagnoses, staging and multidisciplinary discussion. Assessment of resectability is key to drive the treatment sequencing. Association with autoimmune diseases, especially myasthenia gravis, is observed, which impacts the oncological management. Networks are being built at the national and international levels. This article provides an overview of the most recent findings in the diagnosis, staging, histology, and management strategies of thymic tumours.<\/jats:p>","DOI":"10.1183\/16000617.0394-2020","type":"journal-article","created":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T09:59:12Z","timestamp":1634723952000},"page":"200394","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Thymic tumours and their special features"],"prefix":"10.1183","volume":"30","author":[{"given":"Cl\u00e9mence","family":"Basse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2021,10,20]]},"reference":[{"key":"2024102403573544000_30.162.200394.1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv277"},{"key":"2024102403573544000_30.162.200394.2","unstructured":"WHO histological classification of tumours of the thymus. In: Travis WB , Brambilla A , Burke AP , et al. , eds. World Health Organization classification of tumours of the lung, pleura, thymus and heart. Lyon, IARC Press, 2015."},{"key":"2024102403573544000_30.162.200394.3","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31818e105c"},{"key":"2024102403573544000_30.162.200394.4","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000294"},{"key":"2024102403573544000_30.162.200394.5","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181a4b8e0"},{"key":"2024102403573544000_30.162.200394.6","doi-asserted-by":"crossref","first-page":"158e167","DOI":"10.1016\/j.ejca.2020.11.011","article-title":"Impact of expert pathologic review of thymic epithelial tumors on diagnosis and management in a real-life setting: a RYTHMIC study","volume":"143","author":"Molina","year":"2021","journal-title":"Eur J Cancer"},{"key":"2024102403573544000_30.162.200394.7","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e318258f03b"},{"key":"2024102403573544000_30.162.200394.8","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1148\/rg.2017160095","article-title":"ITMIG classification of mediastinal compartments and multidisciplinary approach to mediastinal masses","volume":"37","author":"Carter","year":"2017","journal-title":"Radiographics"},{"key":"2024102403573544000_30.162.200394.9","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.14132665"},{"key":"2024102403573544000_30.162.200394.10","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/RTI.0000000000000444","article-title":"Magnetic resonance imaging for the follow-up of treated thymic epithelial malignancies","volume":"34","author":"Kerpel","year":"2019","journal-title":"J Thorac Imaging"},{"key":"2024102403573544000_30.162.200394.11","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000154"},{"key":"2024102403573544000_30.162.200394.12","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.jtho.2017.06.072","article-title":"Assessment of the ITMIG statement on the WHO histological classification and of the eighth TNM staging of thymic epithelial tumors of a series of 188 thymic epithelial tumors","volume":"12","author":"Meurgey","year":"2017","journal-title":"J Thorac Oncol"},{"key":"2024102403573544000_30.162.200394.13","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/PAI.0b013e318297cdb5","article-title":"Role of PAX-8, CD5, and CD117 in distinguishing thymic carcinoma from poorly differentiated lung carcinoma","volume":"22","author":"Asirvatham","year":"2014","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"2024102403573544000_30.162.200394.14","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1440-1827.1994.tb02936.x","article-title":"A review of 79 thymomas: Modification of staging system and reappraisal of conventional division into invasive and non-invasive thymoma","volume":"44","author":"Koga","year":"1994","journal-title":"Pathol Int"},{"key":"2024102403573544000_30.162.200394.15","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31821e8cff"},{"key":"2024102403573544000_30.162.200394.16","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31821e7b12"},{"key":"2024102403573544000_30.162.200394.17","unstructured":"Thymic tumors. In: Brierley JD , Gosporadowicz MK , Wittekind C , eds. TNM classification of malignant tumours. 8th Edn. Oxford, Wiley and Sons, 2017."},{"key":"2024102403573544000_30.162.200394.18","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31821c4203"},{"key":"2024102403573544000_30.162.200394.19","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/jso.25981","article-title":"Importance of resection for locoregional disease control in Masaoka stage IVA thymic neoplasms","volume":"122","author":"Corsini","year":"2020","journal-title":"J Surg Oncol"},{"key":"2024102403573544000_30.162.200394.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2007.08.051"},{"key":"2024102403573544000_30.162.200394.21","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejso.2018.01.078","article-title":"Mesothelioma and thymic tumors: Treatment challenges in (outside) a network setting","volume":"45","author":"Imbimbo","year":"2019","journal-title":"Eur J Surg Oncol"},{"key":"2024102403573544000_30.162.200394.22","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/j.jtho.2017.07.023","article-title":"Multidisciplinary tumor board decision making for postoperative radiotherapy in thymic epithelial tumors: Insights from the RYTHMIC prospective cohort","volume":"12","author":"Basse","year":"2017","journal-title":"J Thorac Oncol"},{"key":"2024102403573544000_30.162.200394.23","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.lungcan.2016.04.024","article-title":"Sunitinib in patients with advanced thymic malignancies: Cohort from the French RYTHMIC network","volume":"97","author":"Remon","year":"2016","journal-title":"Lung Cancer"},{"key":"2024102403573544000_30.162.200394.24","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ctrv.2018.10.001","article-title":"Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME)","volume":"71","author":"Imbimbo","year":"2018","journal-title":"Cancer Treat Rev"},{"issue":"Suppl. 3","key":"2024102403573544000_30.162.200394.25","first-page":"S177","article-title":"Report of ITMIG 2015 meeting","volume":"7","author":"Detterbeck","year":"2015","journal-title":"J Thorac Dis"},{"key":"2024102403573544000_30.162.200394.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2008.03.055"},{"key":"2024102403573544000_30.162.200394.27","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31821ea567"},{"key":"2024102403573544000_30.162.200394.28","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/icvts\/ivy270","article-title":"Is thymomectomy equivalent to complete thymectomy in non-myasthenic patients with early-stage thymoma?","volume":"28","author":"Fiorelli","year":"2019","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"2024102403573544000_30.162.200394.29","doi-asserted-by":"publisher","DOI":"10.1093\/ejcts\/ezu025"},{"key":"2024102403573544000_30.162.200394.30","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.jtcvs.2019.11.114","article-title":"A national analysis of open versus minimally invasive thymectomy for stage I to III thymoma","volume":"160","author":"Yang","year":"2020","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2024102403573544000_30.162.200394.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2012.07.082"},{"key":"2024102403573544000_30.162.200394.32","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31821ea553"},{"key":"2024102403573544000_30.162.200394.33","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1097\/JTO.0000000000000660","article-title":"Impact of positive nodal metastases in patients with thymic carcinoma and thymic neuroendocrine tumors","volume":"10","author":"Weksler","year":"2015","journal-title":"J Thorac Oncol"},{"key":"2024102403573544000_30.162.200394.34","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/j.athoracsur.2018.07.058","article-title":"Cytoreductive pleurectomy and intrathoracic chemohyperthermia for pleural relapse of thymomas","volume":"107","author":"Maury","year":"2019","journal-title":"Ann Thorac Surg"},{"key":"2024102403573544000_30.162.200394.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2012.10.013"},{"key":"2024102403573544000_30.162.200394.36","doi-asserted-by":"crossref","unstructured":"Hamaji M , Kojima F , Omasa M , et al. A meta-analysis of debulking surgery versus surgical biopsy for unresectable thymoma. Eur J Cardiothorac Surg 2015; 47: 602\u2013607.","DOI":"10.1093\/ejcts\/ezu277"},{"key":"2024102403573544000_30.162.200394.37","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1038\/s41598-020-58692-2","article-title":"Impact of definitive radiotherapy and surgical debulking on treatment outcome and prognosis for locally advanced Masaoka-Koga stage III thymoma","volume":"10","author":"Fan","year":"2020","journal-title":"Sci Rep"},{"key":"2024102403573544000_30.162.200394.38","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31821ea60c"},{"key":"2024102403573544000_30.162.200394.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.02.016"},{"key":"2024102403573544000_30.162.200394.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2008.11.022"},{"key":"2024102403573544000_30.162.200394.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2014.09.124"},{"key":"2024102403573544000_30.162.200394.42","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000128"},{"key":"2024102403573544000_30.162.200394.43","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000099"},{"key":"2024102403573544000_30.162.200394.44","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.jtho.2016.06.011","article-title":"Postoperative radiation therapy is associated with longer overall survival in completely resected stage II and III thymoma-an analysis of the international thymic malignancies interest group retrospective database","volume":"11","author":"Rimner","year":"2016","journal-title":"J Thorac Oncol"},{"key":"2024102403573544000_30.162.200394.45","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3182254ac1"},{"key":"2024102403573544000_30.162.200394.46","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29166"},{"key":"2024102403573544000_30.162.200394.47","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1016\/j.jtho.2016.07.032","article-title":"Postoperative radiotherapy in locally invasive malignancies of the thymus: Patterns of care and survival","volume":"11","author":"Boothe","year":"2016","journal-title":"J Thorac Oncol"},{"key":"2024102403573544000_30.162.200394.48","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jtho.2017.01.002","article-title":"The impact of postoperative radiotherapy for thymoma and thymic carcinoma","volume":"12","author":"Jackson","year":"2017","journal-title":"J Thorac Oncol"},{"key":"2024102403573544000_30.162.200394.49","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.athoracsur.2015.06.034","article-title":"The effectiveness of postoperative radiotherapy in patients with completely resected thymoma: A meta-analysis","volume":"101","author":"Zhou","year":"2016","journal-title":"Ann Thorac Surg"},{"key":"2024102403573544000_30.162.200394.50","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31821ea5f7"},{"key":"2024102403573544000_30.162.200394.51","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1200\/JCO.1994.12.6.1164","article-title":"Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: Final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group","volume":"12","author":"Loehrer","year":"1994","journal-title":"J Clin Oncol"},{"key":"2024102403573544000_30.162.200394.52","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2003.12.010"},{"key":"2024102403573544000_30.162.200394.53","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6690773"},{"key":"2024102403573544000_30.162.200394.54","doi-asserted-by":"publisher","DOI":"10.1093\/icvts\/ivs133"},{"key":"2024102403573544000_30.162.200394.55","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.1997.15.9.3093","article-title":"Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial","volume":"15","author":"Loehrer","year":"1997","journal-title":"J Clin Oncol"},{"key":"2024102403573544000_30.162.200394.56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2013.08.061"},{"key":"2024102403573544000_30.162.200394.57","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1200\/JCO.1996.14.3.814","article-title":"Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organisation for Research and Treatment of Cancer Lung Cancer Cooperative Group","volume":"14","author":"Giaccone","year":"1996","journal-title":"J Clin Oncol"},{"key":"2024102403573544000_30.162.200394.58","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181f20eb3"},{"key":"2024102403573544000_30.162.200394.59","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010601)91:11<2010::AID-CNCR1226>3.0.CO;2-2"},{"key":"2024102403573544000_30.162.200394.60","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.9607"},{"key":"2024102403573544000_30.162.200394.61","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp483"},{"key":"2024102403573544000_30.162.200394.62","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu541"},{"key":"2024102403573544000_30.162.200394.63","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-014-1800-6"},{"key":"2024102403573544000_30.162.200394.64","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/j.jtho.2018.08.005","article-title":"Systemic therapy in advanced thymic epithelial tumors: Insights from the RYTHMIC prospective cohort","volume":"13","author":"Merveilleux du Vignaux","year":"2018","journal-title":"J Thorac Oncol"},{"key":"2024102403573544000_30.162.200394.65","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000296"},{"key":"2024102403573544000_30.162.200394.66","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000370"},{"key":"2024102403573544000_30.162.200394.67","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2012.02.092"},{"key":"2024102403573544000_30.162.200394.68","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000378"},{"key":"2024102403573544000_30.162.200394.69","doi-asserted-by":"crossref","first-page":"7079","DOI":"10.1200\/jco.2006.24.18_suppl.7079","article-title":"A phase II trial of pemetrexed in patients with recurrent thymoma or thymic carcinoma","volume":"24","author":"Loehrer","year":"2006","journal-title":"J Clin Oncol"},{"key":"2024102403573544000_30.162.200394.70","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000298"},{"key":"2024102403573544000_30.162.200394.71","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/CCO.0000000000000564","article-title":"Thymic malignancies: Emerging systemic therapies","volume":"31","author":"Girard","year":"2019","journal-title":"Curr Opin Oncol"},{"key":"2024102403573544000_30.162.200394.72","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0644"},{"key":"2024102403573544000_30.162.200394.73","doi-asserted-by":"crossref","unstructured":"Maury JM , Merveilleux du Vignaux C , Drevet G , et al. Activation of the mTOR\/Akt pathway in thymic epithelial cells derived from thymomas. PLoS One 2019; 14: e0197655.","DOI":"10.1371\/journal.pone.0197655"},{"key":"2024102403573544000_30.162.200394.74","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ccell.2018.01.003","article-title":"The integrated genomic landscape of thymic epithelial tumors","volume":"33","author":"Radovich","year":"2018","journal-title":"Cancer Cell"},{"issue":"Suppl. 5","key":"2024102403573544000_30.162.200394.75","first-page":"V595\u2013V596","article-title":"Comprehensive genomic profiling (CGP) of thymic gland carcinomas","volume":"28","author":"Ross","year":"2017","journal-title":"Ann Oncol"},{"key":"2024102403573544000_30.162.200394.76","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1200\/JCO.2017.74.4078","article-title":"Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy","volume":"36","author":"Zucali","year":"2018","journal-title":"J Clin Oncol"},{"key":"2024102403573544000_30.162.200394.77","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71181-7"},{"key":"2024102403573544000_30.162.200394.78","first-page":"S246","article-title":"Phase II study of sunitinib in patients with thymic carcinoma previously treated with platinum-based chemotherapy (KOSMIC Trial)","volume":"13","author":"Kim","year":"2018","journal-title":"J Thorac Oncol"},{"key":"2024102403573544000_30.162.200394.79","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.lungcan.2016.04.024","article-title":"Sunitinib in patients with advanced thymic malignancies: Cohort from the French RYTHMIC network","volume":"97","author":"Remon","year":"2016","journal-title":"Lung Cancer"},{"key":"2024102403573544000_30.162.200394.80","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S1470-2045(20)30162-5","article-title":"Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial","volume":"21","author":"Sato","year":"2020","journal-title":"Lancet Oncol"},{"key":"2024102403573544000_30.162.200394.81","doi-asserted-by":"publisher","DOI":"10.1084\/jem.191.5.891"},{"key":"2024102403573544000_30.162.200394.82","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.humpath.2016.09.023","article-title":"PD-L1, PD-1, CD4, and CD8 expression in neoplastic and nonneoplastic thymus","volume":"60","author":"Marchevsky","year":"2017","journal-title":"Hum Pathol"},{"key":"2024102403573544000_30.162.200394.83","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40364-019-0177-8","article-title":"Immune biomarkers in thymic epithelial tumors: Expression patterns, prognostic value and comparison of diagnostic tests for PD-L1","volume":"7","author":"Rouquette","year":"2019","journal-title":"Biomark Res"},{"key":"2024102403573544000_30.162.200394.84","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study","volume":"19","author":"Giaccone","year":"2018","journal-title":"Lancet Oncol"},{"key":"2024102403573544000_30.162.200394.85","unstructured":"Cho J , Kim HS , Ku BM , et al. Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: An open-label phase II trial. J Clin Oncol 2018; JCO2017773184."},{"key":"2024102403573544000_30.162.200394.86","doi-asserted-by":"crossref","first-page":"78e86","DOI":"10.1016\/j.ejca.2019.03.012","article-title":"Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study","volume":"113","author":"Katsuya","year":"2019","journal-title":"Eur J Cancer"},{"key":"2024102403573544000_30.162.200394.87","doi-asserted-by":"crossref","first-page":"S130","DOI":"10.1016\/j.jtho.2016.11.333","article-title":"OA18.03: Safety and clinical activity of avelumab (MSB0010718C; Anti-PD-L1) in patients with advanced thymic epithelial tumors (TETs)","volume":"12","author":"Rajan","year":"2017","journal-title":"J Thorac Oncol"}],"container-title":["European Respiratory Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/16000617.0394-2020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:04:28Z","timestamp":1740373468000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/16000617.0394-2020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,20]]},"references-count":87,"journal-issue":{"issue":"162","published-online":{"date-parts":[[2021,10,20]]},"published-print":{"date-parts":[[2021,12,31]]}},"alternative-id":["10.1183\/16000617.0394-2020"],"URL":"https:\/\/doi.org\/10.1183\/16000617.0394-2020","relation":{},"ISSN":["0905-9180","1600-0617"],"issn-type":[{"value":"0905-9180","type":"print"},{"value":"1600-0617","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,20]]}}}